Pfizer, GlaxoSmithKline and Merck & Co disclose payments to US medics

In voluntary disclosures US drugs behemoth Pfizer (NYSE: PFE) and UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday revealed payments made to US physicians and scientists for a variety of profession activities.

Pfizer disclosed that it has paid US doctors and researchers about $177 million last year for a range of professional activities. About 61% of the spending was for clinical trials and other research development activities, $34.4 million went to “expert-led forums,” $18 million on meals and $8.9 million went to “professional advising." In 2010, Pfizer spent a total of $9.4 billion on R&D.

"Pfizer depends on the medical and scientific community for a broad range of activities, from conducting clinical trials to providing insight about patient care needs," said Steve Romano, senior vice president of the company's medicines development group, in a statement, noting that, "through our interactions, we receive valuable information that can help us better serve doctors and patients, or we share information that health care professionals may use to make better treatment decisions for their patients."